Crossmark

Induced Hypertension or Intravenous Milrinone for Cerebral Vasospasm: Why Choose?

Published Online: 2021-11-01

Published Print: 2021-12

Authors

Lakhal, Karim https://orcid.org/0000-0002-5311-3987
Hivert, Antoine

Rozec, Bertrand

Cadiet, Julien
License Information

Text and Data Mining valid from 2021-11-01

Version of Record valid from 2021-11-01
More Information

Article History

Received: 8 October 2021

Accepted: 13 October 2021

First Online: 1 November 2021

Conflicts of interest

: Karim Lakhal has no conflicts of interest in connection with the work submitted. In addition, during the past 3 years, KL received congress registration fees from Sanofi-Aventis (once in 2018), travel fees from MSD France (once in 2017), Gilead Sciences (once in 2017), Pfizer (three times: in 2019, 2020, and 2021), and Correvio Pharma (twice in 2020, once in 2021). Bertrand Rozec has no conflicts of interest in connection with the work submitted. In addition, during the past 5 years, BR received lecture fees from Fisher & Paykel, Baxter International, LFB, Aspen, research grants from Baxter, and consulting fees from LFB and AstraZeneca. None of the other authors have any financial or nonfinancial competing interest in connection with this study.

Document is current